Response by Sperber et al to Letter Regarding Article, "Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)"

Affiliations

¹ Center for Stroke Research Berlin (CSB), Chariteé - Universitätsmedizin Berlin, Berlin, Germany.
² Klinik und Hochschulambulanz fuür Neurologie, Chariteé - Universitätsmedizin Berlin, Berlin, Germany.
³ Center for Stroke Research Berlin (CSB), Chariteé - Universitätsmedizin Berlin, Berlin, Germany, Chariteé - Universitätsmedizin Berlin, Berlin, Germany.

Comment

Pia S Sperber et al. Stroke. 2020 Feb.

. 2020 Feb;51(2):e29.

doi: 10.1161/STROKEAHA.119.028095. Epub 2020 Jan 13.

¹ Center for Stroke Research Berlin (CSB), Chariteé - Universitätsmedizin Berlin, Berlin, Germany.
² Klinik und Hochschulambulanz fuür Neurologie, Chariteé - Universitätsmedizin Berlin, Berlin, Germany.
³ Center for Stroke Research Berlin (CSB), Chariteé - Universitätsmedizin Berlin, Berlin, Germany, Chariteé - Universitätsmedizin Berlin, Berlin, Germany.

No abstract available

Comment on

Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B).
Sperber PS, Siegerink B, Huo S, Rohmann JL, Piper SK, Prüss H, Heuschmann PU, Endres M, Liman TG. Sperber PS, et al. Stroke. 2019 Nov;50(11):3213-3219. doi: 10.1161/STROKEAHA.119.026100. Epub 2019 Sep 17. Stroke. 2019. PMID: 31526121 Clinical Trial.
Letter by Dalmau Regarding Article, "Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)".
Dalmau J. Dalmau J. Stroke. 2020 Feb;51(2):e28. doi: 10.1161/STROKEAHA.119.027885. Epub 2020 Jan 13. Stroke. 2020. PMID: 31928149 No abstract available.